These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10099659)

  • 1. Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
    Shehata N; Pater A; Tang SC
    Cancer Invest; 1999; 17(3):201-5. PubMed ID: 10099659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
    Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH
    Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
    Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
    Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
    Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
    Takimoto CH; Lu ZH; Zhang R; Liang MD; Larson LV; Cantilena LR; Grem JL; Allegra CJ; Diasio RB; Chu E
    Clin Cancer Res; 1996 Mar; 2(3):477-81. PubMed ID: 9816193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G; Etienne MC
    Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population study of dihydropyrimidine dehydrogenase in cancer patients.
    Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
    J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
    Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
    Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
    Saif MW; Seller S; Diasio RB
    JOP; 2008 Mar; 9(2):226-9. PubMed ID: 18326935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
    Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; van Gennip AH
    Eur J Cancer; 1997 Nov; 33(13):2258-64. PubMed ID: 9470816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
    Milano G; Etienne MC
    Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
    Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
    Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.